Pentadecapeptide BPC 157

Phase 2Peptide

HHudson Biotech

Pentadecapeptide BPC 157 is one of 11 small molecule programs targeting Acute. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcuteRecruiting

AcutePhase 2

Recruiting

Competition

Competitive Landscape

11 competitors in Acute

#DrugCompanyPhaseTrials

Fetroja

Shionogi

Approved

1 2

Orencia

Bristol-Myers Squibb

Phase 2

1 3

Vyvgart

Argenx

Phase 2

1 4

Dapansutrile

OOlatec Therapeutics LLC

Phase 3

1 5

Clemastine Fumarate

Novartis

Phase 2

1 6

Resotran

Takeda

Preclinical

1 7

Gen-1124

GGEn1E Lifesciences

Phase 2

1 8

Pentadecapeptide BPC 157

HHudson Biotech

Phase 2

1 9

Nicotine Pouches

JJohns Hopkins University

Phase 1

1 10

S-3,4-Methylenedioxymethamphetamine

UUniversity Hospital, Basel, Switzerland

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Acute

NCT07437547

Clinical

Trials by Indication[1]

Acute1 trial

BPC 157 for Acute Hamstring Muscle Strain Repair

Recruiting·HHudson Biotech·Phase 2·NCT07437547·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pentadecapeptide BPC 157. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentadecapeptide BPC 157 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentadecapeptide BPC 157. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hudson Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: HHudson Biotech

Pentadecapeptide BPC 157

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Acute1 trial

References

Drug Info

Quick Facts

Related News